Skip to content
RecruitingPhase 1

MDMA-Assisted Therapy for Mental Healthcare Providers

NCT07102576 · Rachel Yehuda

Recruiting
Status
Accepting participants
Phase 1
Phase
30
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

This is a phase 1, open-label study to assess changes in mental well-being following MDMA administration within a therapeutic setting, in mental health providers who are in training to become MDMA assisted therapists. Secondary outcome measures will examine the effects on provider burnout, provider self-efficacy, mood, self-compassion, quality of life, and other psychological factors. Participants will work with a co-therapy pair as they engage in a preparatory session, one experimental session with MDMA, and an integration session the following day.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Mental Health Continuum-Short Form (MHC-SF)

    Measured over At baseline and 28 days post-treatment

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * Are at least 18 years at the time of signing the informed consent. * Fluent in English * Able to swallow pills * Agree to have study visits audiovisually recorded * Able to provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of the participant becoming unwell or unreachable. * Must be licensed, license-eligible, or trainees in a relevant healthcare/mental health profession * Must be learning or have been certified to conduct MDMA-assisted therapy through the Lykos MDMA-Assisted Therapy Training program or authorized affiliate program * Body weight of at least 45 kilograms (kg; or 100 pounds (lbs)). Exclusion Criteria * Have engaged in a new form of psychiatric or mental health care within 12 weeks of enrollment * Have a current alcohol or cannabis use disorder of any severity within the 12 months prior to enrollment * Have a substance use disorder of any severity within 12 months prior to enrollment * Any suicidal ideation within the last 6 months * Repetitive or recent use of Ecstasy/MDMA * Current enrollment in any other clinical study involving an investigational study treatment or any other type of medical research, unless approved by the study clinician * Meet diagnostic criteria for a Major Depressive Episode currently or within the prior 3 months or meet diagnostic criteria for a current anxiety disorder assessed * Have a current eating disorder with compensatory behaviors * Have a history of, or a current primary psychotic disorder or bipolar disorder * Previous participation in a clinical trial that included administration of MDMA * Individuals in a personal relationship with the site investigator * Are pregnant or nursing or are able to become pregnant and are not practicing an effective means of contraception

Where

1 study site

FacilityCityRegionCountry
The Parsons Research Center for Psychedelic HealingNew YorkNew YorkUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07102576 on ClinicalTrials.gov →

Last updated in the registry 2026-03-27. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits